Prosecution Insights
Last updated: October 02, 2026

Examiner: BOATENG, AFUA BAMFOAA

Tech Center 1600 • Art Units: 1614 1617 1624

This examiner grants 47% of resolved cases

Analysis

Afua Bamfoaa Boateng is a patent examiner in Tech Center 1600, assigned to Art Unit 1614. Her record includes 73 resolved cases, providing an early look at her examination tendencies. The allowance rate pct for Boateng is 46.6, which indicates that fewer than half of the applications she reviews result in a grant. This 46.6 allowance rate pct suggests a rigorous environment for applicants in Art Unit 1614.

The interview lift pct of 64.4 is exceptionally high, indicating that interviews are a highly effective tool for securing an allowance. This 64.4 interview lift pct suggests that direct communication can dramatically improve the odds of success compared to written prosecution alone. The median days to allowance is 1438, reflecting a lengthy timeline for successful cases. Given the 1438 median days to allowance and the 73 resolved cases, practitioners should prioritize examiner interviews as a primary strategy to navigate the challenges of Tech Center 1600 and potentially reach a resolution more effectively.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

46.6%
Allow Rate
-13.4% vs TC avg
107
Total Applications
+64.4%
Interview Lift
1438
Avg Prosecution Days
Based on 73 resolved cases, 2023–2026

Rejection Statute Breakdown

1.4%
§101 Eligibility
7.7%
§102 Novelty
48.3%
§103 Obviousness
25.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18878148 HERBICIDAL MIXTURES COMPRISING L-GLUFOSINATE OR ITS SALT AND A SECOND HERBICIDE Non-Final OA BASF SE
18697593 PIGMENT SUSPENSION AND COSMETIC AGENT PREPARED USING THE PIGMENT SUSPENSION Non-Final OA HENKEL AG & CO. KGAA
17777002 FIBER REINFORCED COMPOSITIONS AND METHODS OF MANUFACTURE FOR MEDICAL DEVICE APPLICATIONS Final Rejection Evonik Operations GmbH
19194473 POWDER COSMETIC CONTAINING ULTRAVIOLET WAVELENGTH-CONVERTING SUBSTANCE, AND METHOD FOR PRODUCING SAME Non-Final OA Shiseido Company, Ltd.
18089011 PHOTODYNAMIC ANTI-GRAM-POSITIVE BACTERIAL ACTIVITY OF PHARMACEUTICAL-GRADE ROSE BENGAL Final Rejection University of Tennessee Research Foundation
18562459 METHODS FOR INDUCING VASODILATION Non-Final OA THE UNIVERSITY OF MELBOURNE
18870206 ANTIVIRAL COMPOSITION AND MEMBER HAVING SAID COMPOSITION AT SURFACE THEREOF Non-Final OA SHIN-ETSU CHEMICAL CO., LTD.
18716012 HAIR CONDITIONING COMPOSITION FOR IMPROVED DEPOSITION Non-Final OA Conopco, Inc., d/b/a UNILEVER
16980578 HERBICIDAL COMBINATIONS Non-Final OA UPL LTD
18004336 LONG-ACTING FORMULATIONS Final Rejection Janssen Pharmaceutica NV
17784859 NON-VIRAL VECTORS COMPRISING POLYPROPYLENEIMINE Non-Final OA UNIVERSITEIT GENT
18117126 OPHTHALMIC DYE COMPOSITION AND METHOD FOR ADMINISTERING SAME Final Rejection Harrow IP, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month